<p>，/PRNewswire/ -- Schall 律師事務所是一家全國性的股東權益訴訟事務所，提醒投資者注意針對 Replimune Group, Inc.（&#34;Replimune&#34;或&#34;公司&#34;）（NASDAQ: REPL）的集體訴訟，該訴訟因違反 1934 年證券交易法第 10(b) 條和第 20(a) 條以及美國證券交易委員會制定的第 10b-5 條而提起。</p>
<p>在 2024 年 11 月 22 日至 2025 年 7 月 21 日期間（&#34;集體訴訟期間&#34;）購買了公司證券的投資者，鼓勵在 2025 年 9 月 22 日之前與本事務所聯繫。</p>
<p>如果您是遭受損失的股東，請點擊這裏參與。</p>
<p>我們還鼓勵您聯繫 Schall 律師事務所的 Brian Schall，地址為 2049 Century Park East, Suite 2460, Los Angeles, CA 90067，電話 310-301-3335，免費討論您的權利。您也可以通過事務所的網站 www.schallfirm.com 或電子郵件 [email protected] 與我們聯繫。</p>
<p>本案的集體訴訟尚未獲得認證，在認證之前，您並未由律師代表。如果您選擇不採取任何行動，您可以保持缺席集體成員身份。</p>
<p>根據投訴，公司向市場發佈了虛假和誤導性陳述。Replimune 誇大了其針對 RP1（vusolimogene oderparepvec）的 IGNYTE 試驗的前景。公司知道或應該知道該試驗存在重大問題，這將導致 FDA 認為該試驗不充分且控制不當。基於這些事實，公司在集體訴訟期間的公開聲明是虛假且具有重大誤導性的。當市場瞭解到 Replimune 的真相時，投資者遭受了損失。</p>
<p>加入本案以追回您的損失。</p>
<p>Schall 律師事務所代表全球投資者，專注於證券集體訴訟和股東權益訴訟。</p>
<p>本新聞稿在某些司法管轄區可能被視為律師廣告，依據適用法律和倫理規則。</p>
<p><strong>聯繫方式：</strong></p>
<p>Schall 律師事務所</p>
<p>Brian Schall, Esq.,</p>
<p>www.schallfirm.com</p>
<p>辦公室：310-301-3335</p>
<p>[email protected]</p>
<p>來源：Schall 律師事務所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODQwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDQ1UFJfTkVXU19VU1BSX19fX19MQTM4NDA0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODQwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDQ1UFJfTkVXU19VU1BSX19fX19MQTM4NDA0"/></p>

REPL

<p>Schall 律師事務所提醒投資者，針對 Replimune Group, Inc.的證券欺詐違規行為提起了集體訴訟。購買了 Replimune 證券的投資者，時間在 2024 年 11 月 22 日至 2025 年 7 月 21 日之間，鼓勵在 2025 年 9 月 22 日之前與該事務所聯繫。訴訟聲稱 Replimune 在其 RP1 的 IGNYTE 試驗中做出了虛假陳述，當真相被揭露時導致投資者損失。該事務所專注於證券集體訴訟，併為受影響的股東提供免費的諮詢服務</p>

<p>, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. (&#34;Replimune&#34; or &#34;the Company&#34;) (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- Schall 律師事務所是一家全國性的股東權益訴訟事務所，提醒投資者注意針對 Replimune Group, Inc.（&#34;Replimune&#34;或&#34;公司&#34;）（NASDAQ: REPL）的集體訴訟，該訴訟因違反 1934 年證券交易法第 10(b) 條和第 20(a) 條以及美國證券交易委員會制定的第 10b-5 條而提起。</p>
</div><p>Investors who purchased the Company's securities between November 22, 2024 and July 21, 2025, inclusive (the &#34;Class Period&#34;), are encouraged to contact the firm before September 22, 2025.</p>
<div class="lb-trans"><p>在 2024 年 11 月 22 日至 2025 年 7 月 21 日期間（&#34;集體訴訟期間&#34;）購買了公司證券的投資者，鼓勵在 2025 年 9 月 22 日之前與本事務所聯繫。</p>
</div><p>If you are a shareholder who suffered a loss, click here to participate.</p>
<div class="lb-trans"><p>如果您是遭受損失的股東，請點擊這裏參與。</p>
</div><p>We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].</p>
<div class="lb-trans"><p>我們還鼓勵您聯繫 Schall 律師事務所的 Brian Schall，地址為 2049 Century Park East, Suite 2460, Los Angeles, CA 90067，電話 310-301-3335，免費討論您的權利。您也可以通過事務所的網站 www.schallfirm.com 或電子郵件 [email protected] 與我們聯繫。</p>
</div><p>The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.</p>
<div class="lb-trans"><p>本案的集體訴訟尚未獲得認證，在認證之前，您並未由律師代表。如果您選擇不採取任何行動，您可以保持缺席集體成員身份。</p>
</div><p>According to the Complaint, the Company made false and misleading statements to the market. Replimune overstated the prospects of its IGNYTE trial for RP1 (vusolimogene oderparepvec). The Company knew or should have known of material issues with the trial that would result in the FDA finding it was inadequate and poorly controlled. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Replimune, investors suffered damages.</p>
<div class="lb-trans"><p>根據投訴，公司向市場發佈了虛假和誤導性陳述。Replimune 誇大了其針對 RP1（vusolimogene oderparepvec）的 IGNYTE 試驗的前景。公司知道或應該知道該試驗存在重大問題，這將導致 FDA 認為該試驗不充分且控制不當。基於這些事實，公司在集體訴訟期間的公開聲明是虛假且具有重大誤導性的。當市場瞭解到 Replimune 的真相時，投資者遭受了損失。</p>
</div><p>Join the case to recover your losses.</p>
<div class="lb-trans"><p>加入本案以追回您的損失。</p>
</div><p>The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.</p>
<div class="lb-trans"><p>Schall 律師事務所代表全球投資者，專注於證券集體訴訟和股東權益訴訟。</p>
</div><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>
<div class="lb-trans"><p>本新聞稿在某些司法管轄區可能被視為律師廣告，依據適用法律和倫理規則。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>The Schall Law Firm</p>
<div class="lb-trans"><p>Schall 律師事務所</p>
</div><p>Brian Schall, Esq.,</p>
<div class="lb-trans"><p>Brian Schall, Esq.,</p>
</div><p>www.schallfirm.com</p>
<div class="lb-trans"><p>www.schallfirm.com</p>
</div><p>Office: 310-301-3335</p>
<div class="lb-trans"><p>辦公室：310-301-3335</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE The Schall Law Firm</p>
<div class="lb-trans"><p>來源：Schall 律師事務所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODQwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDQ1UFJfTkVXU19VU1BSX19fX19MQTM4NDA0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA38404&amp;Transmission_Id=202507281045PR_NEWS_USPR_____LA38404&amp;DateId=20250728"/></p>

REPL 投資者有機會與 Schall 律師事務所合作，主導 Replimune Group, Inc.的證券欺詐訴訟